Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naive advanced or metastatic esophagogastric cancer

Markus Moehler,Rolf Mahlberg,Volker Heinemann,Radka Obermannová,Eugen Kubala,Bohuslav Melichar,Arndt Weinmann,Paul Scigalla,Marietta Tesařová,Petr Janda,Fabienne Hédouin-Biville,Wasat Mansoor

Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naive advanced or metastatic esophagogastric cancer

2017

Markus Moehler
Rolf Mahlberg
Volker Heinemann
Radka Obermannová
Eugen Kubala
Bohuslav Melichar
Arndt Weinmann
Paul Scigalla
Marietta Tesařová
Petr Janda
Fabienne Hédouin-Biville
Wasat Mansoor

Background This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS).

Keywords:

General surgery
Medicine
Maximum tolerated dose
Cancer
Chemotherapy
Epirubicin
Oxaliplatin
Oncology
phase i study
esophagogastric cancer
in patient
Internal medicine
Surgical oncology
chemotherapy naive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations